Photodynamic therapy and photobiomodulation in the treatment of erythematotelangiectatic and papulopustular rosacea subtypes: a pilot, open-label, non-randomized, controlled prospective study
Russian Journal of Skin and Venereal Diseases · 31.05.2026 · 29 (3) · 375-389
DOI: 10.17816/dv701947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 31.05.2026. Verfasst von Yulia Yu. Chebotareva und 5 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Data on the clinical efficacy of combined photodynamic therapy (PDT) and photobiomodulation (PBM) in rosacea are limited to a small number of studies, mostly based on subjective assessment methods. Only a few studies include objective instrumental parameters reflecting skin microcirculation and standardized clinical scales. AIM: To evaluate the clinically and instrumentally confirmed efficacy of combined PDT and PBM together with specialized home skincare, including topical ivermectin cream, in patients with erythematotelangiectatic and papulopustular subtypes of rosacea. METHODS: This pilot study, with within-group comparison of pre- and post-treatment parameters, included 9 patients aged 27–44 years with rosacea, facial erythema, telangiectasia, and papulopustular lesions, who were divided into 3 groups of 3 patients each depending on the clinical subtype of rosacea and the treatment regimen (PDT+PBM, 6 sessions at 7-day intervals) combined with a home skincare line. Assessment methods included photographic documentation, ultrasound examination with Doppler modes to assess vascularization, and the GAIS (Global Aesthetic Improvement Scale), DLQI (Dermatology Life Quality Index), IGA (Investigator Global Assessment), and RDAS (Rosacea Diagnostic Assessment Scale). RESULTS: Improvement in clinical parameters was observed in all treatment groups, confirmed by objective and subjective assessment methods. Specifically, lower scores after treatment compared with baseline indicated a transition from moderate erythema to very mild erythema on the IGA (p 0.001), a reduction in overall rosacea symptom severity on the RDAS (p 0.001), and a shift from moderate to minimal impact of the disease on quality of life on the DLQI (p 0.001). According to 3D Antera 3D imaging, a reduction in the vascular component and changes in vascular pattern homogeneity were observed in all three groups, as well as statistically significant improvement in the microvascular network parameters. Group 3 showed the greatest improvement, with a 52.4% reduction in the vascularization index (p=0.005), a 35.2% decrease in vessel diameter (p=0.003), and a 28.7% reduction in vessel depth (p=0.023). In addition, patients reported a subjective reduction in facial discomfort. CONCLUSION: These data indicate the potential efficacy of PDT and PBM in combination with home skincare. The combined approach using ivermectin cream in the treatment of various rosacea subtypes shows the most pronounced therapeutic outcomes.
Zitieren
APA
Chebotareva, Y. Y., Glushkova, M. I., Privalova, E. G., Markelova, I. A., Volkova, N. V., & Khokhlova, T. A. (2026). Photodynamic therapy and photobiomodulation in the treatment of erythematotelangiectatic and papulopustular rosacea subtypes: a pilot, open-label, non-randomized, controlled prospective study. Russian Journal of Skin and Venereal Diseases, 29(3), 375-389. https://doi.org/10.17816/dv701947
Vancouver
Chebotareva YY, Glushkova MI, Privalova EG, Markelova IA, Volkova NV, Khokhlova TA. Photodynamic therapy and photobiomodulation in the treatment of erythematotelangiectatic and papulopustular rosacea subtypes: a pilot, open-label, non-randomized, controlled prospective study. Russian Journal of Skin and Venereal Diseases. 2026;29(3):375-389. doi:10.17816/dv701947
BibTeX
@article{Chebotareva2026,
author = {Chebotareva, Yulia Yu. and Glushkova, Maria I. and Privalova, Ekaterina G. and Markelova, Irina A. and Volkova, Natalia V. and Khokhlova, Tatiana A.},
title = {Photodynamic therapy and photobiomodulation in the treatment of erythematotelangiectatic and papulopustular rosacea subtypes: a pilot, open-label, non-randomized, controlled prospective study},
journal = {Russian Journal of Skin and Venereal Diseases},
year = {2026},
volume = {29},
number = {3},
pages = {375--389},
doi = {10.17816/dv701947}
}
EUVIMED